Actively Recruiting
Open-Label Study of WGI-0301 with Sorafenib Compared to Sorafenib Alone in Adults with Advanced Hepatocellular Carcinoma
Led by Zhejiang Haichang Biotech Co., Ltd. · Updated on 2026-09-11
60
Participants Needed
9
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the maximum tolerated dose MTD of WGI-0301 combined with Sorafenib for adults with advanced hepatocellular carcinoma HCC who have previously received PD-1 or PD-L1 immune checkpoint inhibitors. This phase 2 study aims to assess the safety and effectiveness of this combination treatment compared to Sorafenib alone in patients with advanced, unresectable HCC. The study has two stages Stage 1 involves dose escalation to find the MTD or recommended Phase 2 dose RP2D of WGI-0301 combined with Sorafenib. Stage 2 expands to compare two dose levels of WGI-0301 plus standard dose Sorafenib against standard dose Sorafenib alone. WGI-0301 is given as a weekly intravenous infusion, while Sorafenib is taken orally twice daily continuously. Participants will undergo screening for eligibility, then receive assigned treatments based on randomization. Researchers will monitor tumor response using RECIST 1.1 criteria and evaluate safety, tolerability, and anti-tumor activity over about two years. Assessments include imaging to measure tumor lesions, laboratory tests, and clinical evaluations during treatment and follow-up periods to track outcomes and side effects.
CONDITIONS
Brief Title
Phase 2 Study of WGI-0301 for Advanced HCC
Research Team
A
Angela Men, MD., Ph.D
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here